PURPOSE: To evaluate the long-term clinical outcomes of retinal pigment epithelium (RPE) tears after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (AMD). METHODS: The authors performed a retrospective chart review of 13 eyes of 13 patients who developed RPE tears after intravitreal anti-VEGF injection between February 2009 and June 2013. We investigated continuation of the treatment after tear, visual acuity, presence of cystoid macular edema, and central macular thickness (CMT) using optical coherence tomography (OCT) before and after treatment and visual outcomes depending on foveal sparing. RESULTS: After RPE tear, 12 of 13 patients continued injection of an anti-VEGF agent. The average number of injections was 6.08 +/- 5.18. Mean visual acuity immediately after tear was 1.65 +/- 0.8 log MAR, and that at the last visit was 1.82 +/- 0.88 log MAR. Nine eyes with macular edema in OCT continued receiving injection, and improvement of macular edema was observed in four eyes at the final visit. The final visual acuity of patients with foveal involvement was 2.17 +/- 0.49 log MAR, which was worse than the 1.51 +/- 1.06 log MAR in patients without foveal involvement, although the difference was not significant (p = 0.295). CONCLUSIONS: When anti-VEGF injections were continued after RPE tear, no improvement in visual acuity was observed, although better anatomical outcomes did result. Patients with foveal involvement had worse visual acuity than patients without foveal involvement, but the difference was not significant.
Endothelial Growth Factors ; Humans ; Intravitreal Injections ; Macular Degeneration* ; Macular Edema ; Retinal Pigment Epithelium ; Retinaldehyde* ; Retrospective Studies ; Tomography, Optical Coherence ; Visual Acuity

PURPOSE: Intravitreal anti-vascular endothelial growth factor (VEGF) treatment has become an important part in the treatment of neovascular age-related macular degeneration (AMD). In the present study we describe the clinical feature of retinal pigment epithelium (RPE) tears after intravitreal injection of anti-VEGF agent and compared the tear group to the control group. METHODS: In this retrospective case series, data of 11 patients with eyes that developed RPE tears after intravitreal anti-VEGF injection (8 ranibizumab and 3 bevacizumab) were collected and analyzed. The tear group included 11 patients with eyes that developed RPE tears and the control group included 22 patients with no RPE tears after treatment. We investigated age, gender, bilaterality, duration from injection to tear, pigment epithelial detachment (PED) height and diameter, along with central retinal thickness (CMT) using optical coherence tomography (OCT), fluorescein angiography (FAG), and visual acuities before and after treatment. RESULTS: The mean age of the tear group was 81.36 +/- 5.55 years which was significantly different from the control group's mean age of 74.82 +/- 5.28 years (p = 0.003). OCT findings showed PED greatest linear dimension (GLD) was 2978.45 +/- 947.69 microm in the tear group and 2250.23 +/- 988.49 microm in the control group (p = 0.027). PED height was 507.09 +/- 153.97 microm in the tear group and 353.23 +/- 199.42 microm in the control group (p = 0.010). CMT was 431.64 +/- 200.33 microm in the tear group and 289.95 +/- 61.27 microm in the control group (p = 0.005). There was no significant difference between groups according to gender, bilaterality, visual acuities, and subretinal fluid based on OCT and FAG findings. In the tear group, visual acuities before and after the tear were not significantly different. CONCLUSIONS: Old age and eyes with high and wide PED appear to be more vulnerable to RPE tear. Further investigation with a larger number of patients is needed to further confirm these results.
Antibodies, Monoclonal, Humanized ; Endothelial Growth Factors ; Eye ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Macular Degeneration* ; Retinal Pigment Epithelium* ; Retinaldehyde* ; Retrospective Studies ; Risk Factors* ; Subretinal Fluid ; Tomography, Optical Coherence ; Visual Acuity ; Bevacizumab ; Ranibizumab

PURPOSE: To report the outcomes after the implantation of intrastromal corneal ring segments (KeraRing(R)) by manual tunnel creation for the correction of keratoconus. METHODS: The present retrospective case series was comprised of 12 eyes of 11 consecutive keratoconic patients. Intrastromal corneal ring segments (KeraRing(R)) were implanted for keratoconus correction after manual tunnel creation. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refractive outcome, and complete ophthalmologic examinations were performed before and after surgery at 1 day, 1 week, 3 months, and 6 months. Corneal topography was measured before surgery, 6 months after surgery and during any necessary follow-up visits. RESULTS: Intrastromal corneal ring segments (KeraRing(R)) implantation significantly increased BCVA from logMAR 0.47 +/- 0.19 to logMAR 0.28 +/- 0.17 (P < 0.05) and decreased the spherical equivalent from -6.03 +/- 3.24 D to -2.24 +/- 1.96 D. The simulated keratometric value in the Orbscan IIz significantly decreased in K maximum from 50.7 +/- 2.93D to 47.65 +/- 3.15 D and in K minimum from 47.65 +/- 3.15 D to 44.92 +/- 2.80 D. CONCLUSIONS: Intrastromal corneal ring segments implantation (KeraRing(R)) by manual tunnel creation appears to be effective in improving BCVA and reducing corneal astigmatism and keratometric value in keratoconic patients. KeraRing(R) may delay or prevent the need for a corneal graft, and reduce the contact lens intolerance.
Astigmatism ; Corneal Topography ; Eye ; Follow-Up Studies ; Humans ; Keratoconus ; Retrospective Studies ; Transplants ; Visual Acuity

PURPOSE: To evaluate the short-term effect of intravitreal aflibercept (Eylea(R); Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA and Bayer, Basel, Switzerland) on the visual outcomes and retinal anatomic changes of patients with polypoidal choroidal vasculopathy (PCV). METHODS: Intravitreal Eylea(R) was injected into 16 eyes of 16 patients with PCV in this retrospective case study. After therapy, the patients were followed up for over 3 months. Changes in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) using optical coherence tomography (OCT) and abnormal vasculature on indocyanine green angiography (ICGA) were evaluated. RESULTS: The mean log MAR BCVA was 0.75 +/- 0.60 at baseline, 0.74 +/- 0.60 and 0.71 +/- 0.63 at 1 and 2 months, respectively (p > 0.05) and 0.57 +/- 0.53 at 3 months (p < 0.05) after treatment. The mean CFT was 379 +/- 130 microm at baseline, 281 +/- 92 microm, 247 +/- 54 microm, and 231 +/- 51 microm at 1, 2, and 3 months, respectively, after treatment (p < 0.05). Complete resolution was 43%, 55%, and 50% at 1, 2, and 3 months, respectively in pigment epithelial detachment (PED), 67%, 83%, and 92% at 1, 2, and 3 months, respectively in subretinal fluid (SRF) and 33%, 60%, and 60% at 1, 2, and 3 months, respectively in intraretinal fluid (IRF) using OCT. The polypoidal lesions in ICGA decreased in 12 of 14 eyes (86%). CONCLUSIONS: Intravitreal injection of Eylea(R) with PCV reduced CFT due to decreased retinal PED, SRF, IRF and occluded effectively the polypoidal lesion leaking. Compared with baseline, mean BCVA at the 3-month follow-up was significantly improved.
Angiography ; Choroid* ; Follow-Up Studies ; Humans ; Indocyanine Green ; Intravitreal Injections ; Retinaldehyde ; Retrospective Studies ; Subretinal Fluid ; Tomography, Optical Coherence ; Visual Acuity